(AOB)

American Oriental Bioengineering Inc.

Close Price:
1.52

Change:
-0.02 Stock Price Decrease0.02

% Change:
-0.012987012987012987012987013 Stock Price Decrease1.30 %

Date:
3/16/2012

52 Week:
1.11 - 5.56

Prev Close:
1.54

Open:
0.00

Volume:
580,090

90D Avg. Volume:
75,113

3/16/2012 Range:
1.41 - 1.56

Market Cap:
59,660,000

Trailing PE Ratio:
4.47

Shares Out:
39,250,000

EPS:
0.34

Yield:
0.00

Dividend:
0.00

Dividend Date:
-

Quarter End:
6/30/2012

American Oriental Bioengineering Inc.

Sector: Healthcare

Industry: Biotechnology

Website: www.bioaobo.com

Business Summary: American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. The company?s principal prescription pharmaceutical products include Shuanghuanglian Lyophilized Injection Powder (SHL Injection Powder), an anti-viral injection for treating respiratory infections, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel (CE Gel) that is used to alleviate bedwetting. Its over-the-counter pharmaceutical products comprise Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. The company also markets various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. American Oriental Bioengineering sells its products primarily to hospitals, clinics, pharmacies, and retail outlets in China through its sales professionals and distributors. The company is based in Beijing, the People?s Republic of China.


1 Liangshuihe First Avenue
Beijing E-Town Economic and Technology Development Area E-To
Beijing, 100176 China China
P: 86 10 5982 2039
F: 86 10 8785 7429

AOB Earnings Calendar

Q1:
Dec
31
 -
Mar
30
Q2:
Mar
31
 -
Jun
30
Q3:
Jun
30
 -
Sep
29
Q4:
Sep
30
 -
Dec
30
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
12/31/2009
 
 
 
$94,425
$0
$72,230
$10,016
$0
$177,917
$57,326
$124,444
$33,164
$172,300
$0
$7,909
$3,422
$576,482
 
 
$30,938
$13,837
$2,199
$46,974
$115,744
$0
$18,708
$533
$0
$181,959
 
$0
$0
$1
$466
$0
$0
$199,830
$3,052
$394,523
$189,059
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
YoY
 
 
 
22.6%
0.0%
73.5%
(23.2%)
0.0%
34.3%
4.3%
0.7%
16.2%
(0.2%)
0.0%
(25.1%)
160.4%
10.0%
 
 
(7.2%)
32.3%
(2.4%)
2.0%
(0.3%)
0.0%
16.3%
(18.3%)
0.0%
1.7%
 
0.0%
0.0%
0.0%
497.4%
0.0%
0.0%
2.1%
669.4%
14.3%
31.3%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
12/31/2008
 
 
 
$77,034
$0
$41,631
$13,042
$0
$132,452
$54,963
$123,540
$28,543
$172,679
$0
$10,563
$1,314
$524,055
 
 
$33,321
$10,462
$2,253
$46,036
$116,074
$0
$16,084
$652
$0
$178,847
 
$0
$0
$1
$78
$0
$0
$195,742
($536)
$345,208
$143,986
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
YoY
 
 
 
(53.7%)
0.0%
80.5%
6.3%
0.0%
(36.0%)
22,518.5%
150.8%
26.5%
135.6%
0.0%
0.0%
(12.3%)
48.2%
 
 
135.1%
19.8%
(36.5%)
74.0%
7,388.6%
0.0%
27.4%
0.0%
0.0%
340.2%
 
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
1.4%
(103.0%)
10.3%
(33.7%)
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
6/30/2010
 
 
 
$97,537
$0
$73,255
$19,017
$0
$191,157
$57,441
$124,770
$33,164
$168,924
$0
$7,968
$2,967
$586,391
 
 
$29,191
$10,123
$4,843
$44,157
$115,711
$3,872
$15,653
$521
$0
$179,914
 
$0
$0
$1
$260
$0
$0
$201,807
$4,988
$406,477
$204,389
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
QoQ
 
 
 
21.5%
0.0%
109.1%
13.0%
0.0%
24.5%
3.6%
2.3%
16.2%
(0.3%)
0.0%
(23.9%)
123.4%
8.4%
 
 
2.3%
3.4%
92.9%
8.1%
(0.1%)
0.0%
(1.9%)
(2.3%)
0.0%
3.9%
 
0.0%
0.0%
0.0%
(33.3%)
0.0%
0.0%
2.6%
1,122.1%
10.6%
20.5%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
3/31/2010
 
 
 
$98,997
$0
$59,620
$19,839
$0
$179,950
$57,461
$124,726
$33,164
$170,286
$0
$7,930
$3,194
$576,712
 
 
$26,120
$13,744
$3,140
$43,004
$115,728
$3,301
$15,738
$528
$0
$178,298
 
$0
$0
$1
$563
$0
$0
$200,408
$3,144
$398,414
$194,964
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
QoQ
 
 
 
23.3%
0.0%
63.9%
10.5%
0.0%
32.8%
3.4%
1.5%
16.2%
(0.3%)
0.0%
(23.3%)
141.6%
9.9%
 
 
4.8%
27.5%
14.7%
11.8%
(0.1%)
0.0%
(2.3%)
(19.5%)
0.0%
4.3%
 
0.0%
0.0%
0.0%
621.8%
0.0%
0.0%
2.1%
980.7%
12.6%
26.1%
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
12/31/2009
$41,421
 
$13,532
($239)
($20,112)
$3,657
$3,154
($15,886)
$25,409
 
($3,979)
($239)
$5,372
$1,153
 
$0
$0
($3,220)
$0
($3,220)
$447
$23,342
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
YoY
(13.4%)
 
28.3%
(101.3%)
(47.8%)
(70.2%)
323.4%
(1,439.5%)
(67.3%)
 
94.6%
98.9%
103.3%
100.4%
 
0.0%
0.0%
(102.9%)
100.0%
(104.0%)
(84.6%)
124.4%
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
12/31/2008
$47,806
 
$10,546
$18,797
($13,603)
$12,282
$745
$1,186
$77,759
 
($73,136)
($22,380)
($161,859)
($257,374)
 
$0
$0
$110,947
($29,999)
$80,948
$2,894
($95,774)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
YoY
10.4%
 
110.0%
1,336.0%
(329.9%)
287.6%
72.1%
123.9%
72.4%
 
(1,734.8%)
0.0%
(145.8%)
(268.5%)
 
0.0%
(100.0%)
2,848.9%
0.0%
(16.4%)
(55.7%)
(221.8%)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
6/30/2010
$5,124
 
$4,208
$286
($13,721)
$5,119
$808
$147
$1,977
 
($275)
$1
($14)
($288)
 
$0
$0
($1,489)
$0
($1,489)
$535
$777
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
QoQ
(62.9%)
 
47.8%
(79.7%)
(13,044.3%)
38.3%
(20.9%)
394.0%
(91.4%)
 
5.5%
101.5%
(100.3%)
(105.9%)
 
0.0%
0.0%
(48.6%)
0.0%
(48.6%)
645.9%
(97.1%)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
3/31/2010
$3,123
 
$4,050
($15)
$12,370
($3,675)
($9,805)
($268)
$5,763
 
($1,090)
($12)
($20)
($1,122)
 
$0
$0
($110)
$0
($110)
$41
$4,530
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
QoQ
(60.3%)
 
16.0%
87.5%
96.8%
58.6%
(101.6%)
(87.4%)
58.2%
 
(175.9%)
88.6%
(2,100.0%)
(124.8%)
 
0.0%
0.0%
(711.1%)
0.0%
(711.1%)
(60.2%)
38.8%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
12/31/2010
$305,944
$148,187
$157,758
 
$15,365
$105,361
$0
$6,662
$0
$30,370
 
($205)
$24,650
$0
$24,650
$8,336
$28
$16,726
 
 
$0
$0
$0
$0
$16,341
$0
$16,341
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
YoY
3.3%
14.5%
(5.4%)
 
94.0%
12.0%
0.0%
10.3%
0.0%
(48.3%)
 
64.0%
(54.8%)
0.0%
(54.8%)
(36.9%)
(76.5%)
(61.5%)
 
 
0.0%
0.0%
0.0%
0.0%
(60.5%)
0.0%
(60.5%)
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
12/31/2009
$296,151
$129,368
$166,783
 
$7,922
$94,062
$0
$6,039
$0
$58,760
 
($570)
$54,519
$0
$54,519
$13,217
$119
$43,496
 
 
$0
$0
$0
$0
$41,421
$0
$41,421
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
YoY
11.9%
42.1%
(3.9%)
 
0.0%
1.5%
(100.0%)
37.8%
0.0%
(8.7%)
 
(763.6%)
(13.6%)
(100.0%)
(9.9%)
3.9%
525.0%
(9.0%)
 
 
0.0%
0.0%
0.0%
0.0%
(13.4%)
0.0%
(13.4%)
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
12/31/2010
$83,365
$40,967
$42,398
 
$4,611
$30,084
$0
$1,760
$0
$5,943
 
($119)
$4,513
$0
$4,513
$1,758
$8
$2,959
 
 
$0
$0
$0
$0
$2,763
$0
$2,763
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
QoQ
(16.7%)
(13.6%)
(19.4%)
 
(14.9%)
(2.0%)
0.0%
10.6%
0.0%
(60.1%)
 
70.7%
(70.7%)
100.0%
(70.7%)
(53.2%)
0.0%
(78.9%)
 
 
0.0%
0.0%
0.0%
0.0%
(76.3%)
0.0%
(76.3%)
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
9/30/2010
$91,533
$44,251
$47,282
 
$4,725
$31,904
$0
$1,682
$0
$8,971
 
($68)
$7,690
$0
$7,690
$2,366
$8
$5,573
 
 
$0
$0
$0
$0
$5,331
$0
$5,331
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
QoQ
16.1%
27.6%
7.1%
 
403.1%
10.7%
0.0%
(9.7%)
0.0%
(40.2%)
 
(38.8%)
(56.3%)
(100.0%)
(42.1%)
(27.4%)
900.0%
(41.1%)
 
 
0.0%
0.0%
0.0%
0.0%
(46.8%)
100.0%
53.2%